FDA grants Pfizer COVID-19 vaccine priority review for full approval
Pfizer today said its COVID-19 vaccine will receive a priority review from the Food and Drug Administration, indicating that Pfizer has completed its rolling submission of its application for the vaccine’s full authorization. The company’s Biologics License Application, which is intended for individuals age 16 and older, is supported by clinical date from its phase 3 clinical trial.
Related News Articles
Headline
Pfizer Inc. today announced that the federal government has agreed to purchase an additional 200 million doses of its COVID-19 vaccine. The deal raises the…
Headline
The Health Resources and Services Administration yesterday awarded rural health clinics about $49,500 each for outreach to increase COVID-19 vaccinations in…
Perspective
The widespread belief that we have completely turned the corner in our fight against COVID-19 does not apply equally to all parts of the country. In many…
Headline
The AHA Board of Trustees yesterday adopted a policy statement that supports hospitals and health systems that adopt mandatory COVID-19 vaccination…
Headline
The AHA, American Medical Association and American Nurses Association today released a public service announcement urging the American public to “ask questions…
Headline
The Food and Drug Administration today revoked its emergency use authorization for the Curative SARS-Cov-2 Assay test because the manufacturer has…